BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maltais F, Buhl R, Koch A, Amatto VC, Reid J, Grönke L, Bothner U, Voß F, Mcgarvey L, Ferguson GT. β-Blockers in COPD. Chest 2018;153:1315-25. [DOI: 10.1016/j.chest.2018.01.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Ruzieh M, Baugh AD, Al Jebbawi L, Edwards ES, Jia KQ, Dransfield MT, Foy AJ. Beta-blocker use in patients with chronic obstructive pulmonary disease: A systematic review: A systematic review of βB in COPD. Trends Cardiovasc Med 2021:S1050-1738(21)00139-0. [PMID: 34856338 DOI: 10.1016/j.tcm.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chapman KR, Wise RA, Scirica BM, Bhatt DL, Daoud SZ, Lythgoe D, Gil EG. Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. Respir Res 2021;22:272. [PMID: 34686204 DOI: 10.1186/s12931-021-01861-2] [Reference Citation Analysis]
3 Gulea C, Zakeri R, Alderman V, Morgan A, Ross J, Quint JK. Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison. Respir Res 2021;22:64. [PMID: 33622362 DOI: 10.1186/s12931-021-01661-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Leitao Filho FS, Choi L, Sin DD. Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly. Curr Opin Pulm Med 2021;27:125-31. [PMID: 33332878 DOI: 10.1097/MCP.0000000000000748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ferguson GT, Maltais F, Karpel J, Bothner U, Kloer I, Trampisch M, Buhl R. Long-term safety of tiotropium/olodaterol in older patients with moderate-to-very-severe COPD in the TONADO® studies. NPJ Prim Care Respir Med 2020;30:53. [PMID: 33277507 DOI: 10.1038/s41533-020-00212-w] [Reference Citation Analysis]
6 Matera MG, Page CP, Calzetta L, Rogliani P, Cazzola M. Pharmacology and Therapeutics of Bronchodilators Revisited. Pharmacol Rev 2020;72:218-52. [PMID: 31848208 DOI: 10.1124/pr.119.018150] [Cited by in Crossref: 36] [Cited by in F6Publishing: 45] [Article Influence: 18.0] [Reference Citation Analysis]
7 Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, Horio T, Hoshide S, Ikeda S, Ishimitsu T, Ito M, Ito S, Iwashima Y, Kai H, Kamide K, Kanno Y, Kashihara N, Kawano Y, Kikuchi T, Kitamura K, Kitazono T, Kohara K, Kudo M, Kumagai H, Matsumura K, Matsuura H, Miura K, Mukoyama M, Nakamura S, Ohkubo T, Ohya Y, Okura T, Rakugi H, Saitoh S, Shibata H, Shimosawa T, Suzuki H, Takahashi S, Tamura K, Tomiyama H, Tsuchihashi T, Ueda S, Uehara Y, Urata H, Hirawa N. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res 2019;42:1235-481. [PMID: 31375757 DOI: 10.1038/s41440-019-0284-9] [Cited by in Crossref: 322] [Cited by in F6Publishing: 457] [Article Influence: 161.0] [Reference Citation Analysis]
8 Li XF, Mao YM. Beta-blockers in COPD: A systematic review based on recent research. Life Sci 2020;252:117649. [PMID: 32275936 DOI: 10.1016/j.lfs.2020.117649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
9 Vahdatpour CA, Luebbert JJ, Palevsky HI. Atrial arrhythmias in chronic lung disease-associated pulmonary hypertension. Pulm Circ 2020;10:2045894020910685. [PMID: 32215200 DOI: 10.1177/2045894020910685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Weiss A, Porter S, Rozenberg D, O'Connor E, Lee T, Balter M, Wentlandt K. Chronic Obstructive Pulmonary Disease: A Palliative Medicine Review of the Disease, Its Therapies, and Drug Interactions. J Pain Symptom Manage 2020;60:135-50. [PMID: 32004618 DOI: 10.1016/j.jpainsymman.2020.01.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
11 Blair HA. Tiotropium/Olodaterol: A Review in COPD. Drugs 2019;79:997-1008. [PMID: 31119643 DOI: 10.1007/s40265-019-01133-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
12 Derom E, Brusselle GG, Joos GF. The once-daily fixed-dose combination of olodaterol and tiotropium in the management of COPD: current evidence and future prospects. Ther Adv Respir Dis 2019;13:1753466619843426. [PMID: 31002020 DOI: 10.1177/1753466619843426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Crump LH, Benfield M, Ramey C, Arcara A, Yang S, Brown J, Mospan G, Mospan C. Drug updates and approvals: 2019 in review. Nurse Pract 2019;44:21-32. [PMID: 31658218 DOI: 10.1097/01.NPR.0000605508.04187.b2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Suissa S, Ernst P. Beta-Blockers in COPD: A Methodological Review of the Observational Studies. COPD 2018;15:520-5. [PMID: 30822238 DOI: 10.1080/15412555.2018.1554637] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
15 Sessa M, Mascolo A, Rasmussen DB, Kragholm K, Jensen MT, Sportiello L, Rafaniello C, Tari GM, Pagliaro C, Andersen M, Rossi F, Capuano A. Beta-blocker choice and exchangeability in patients with heart failure and chronic obstructive pulmonary disease: an Italian register-based cohort study. Sci Rep 2019;9:11465. [PMID: 31391573 DOI: 10.1038/s41598-019-47967-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Mersfelder TL, Shiltz DL. β-Blockers and the Rate of Chronic Obstructive Pulmonary Disease Exacerbations. Ann Pharmacother 2019;53:1249-58. [PMID: 31271049 DOI: 10.1177/1060028019862322] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Gulea C, Zakeri R, Quint JK. Effect of beta-blocker therapy on clinical outcomes, safety, health-related quality of life and functional capacity in patients with chronic obstructive pulmonary disease (COPD): a protocol for a systematic literature review and meta-analysis with multiple treatment comparison. BMJ Open 2018;8:e024736. [PMID: 30429149 DOI: 10.1136/bmjopen-2018-024736] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Melani AS. Olodaterol for the treatment of chronic obstructive pulmonary disease: a narrative review. Expert Opinion on Pharmacotherapy 2018;19:1603-11. [DOI: 10.1080/14656566.2018.1518431] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
19 Cazzola M, Matera MG. Combining Dual Bronchodilation and β-Blockade in Patients With an Overlap Between COPD and Cardiovascular Diseases. Chest 2018;153:1289-91. [DOI: 10.1016/j.chest.2018.01.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]